Human Urinary Kallidinogenase
ApprovedProtein / enzyme
Human Urinary Kallidinogenase is one of 78 small molecule programs targeting Stroke. It is currently in Approved.
3
Indications
7
Total Trials
4
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1Human Urinary Kallidinogenase
XXuanwu Hospital, Beijing
Approved
Activase
RochePreclinical
Zometa
PfizerPreclinical
Savella
AbbViePreclinical
Pradaxa
Boehringer IngelheimPreclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Zantac 150
CChattem
Preclinical
Haldol
DDePuy Orthopaedics
Preclinical
Carbidopa-Levodopa
Neurocrine BiosciencesPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ischemic stroke4 trials
Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke
Not yet recruiting·—·N/A·NCT07483281·220 enrolled
Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment
Recruiting·—·N/A·NCT06848894·1,204 enrolled
Show 1 more trial
Effects of Human Urinary Kallidinogenase on Early Improvement and Functional Outcomes in Acute Ischemic Stroke (TK-SPEED)
Not yet recruiting·—·N/A·NCT06132880·540 enrolled
Cerebral Infarction1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Approved[1]
- Company
- XXuanwu Hospital, Beijing